Exelixis (EXEL)
(Delayed Data from NSDQ)
$38.67 USD
-0.27 (-0.69%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $38.66 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXEL 38.67 -0.27(-0.69%)
Will EXEL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EXEL
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Here's Why Exelixis (EXEL) is a Strong Value Stock
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Other News for EXEL
Is EXEL preparing to trend higher? 20 Day Moving Average Support shows up after dropping 0.69%
Notable Two Hundred Day Moving Average Cross - EXEL
Is EXEL positioned for a breakdown? Stochastic Sell Signal shows up after declining 1.24%
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)
Is EXEL gathering momentum? NR7 shows up after declining 1.61%